

1. Commitment to Achieving Net Zero

Sharpak Healthcare Ltd is committed to achieving Net Zero emissions by 2040. This accelerated target aligns with the NHS Net Zero Supplier Roadmap and the wider UK environmental agenda. As a manufacturer of critical healthcare products, we recognise our responsibility to follow a *Responsible Pathway to Net Zero* that supports the NHS in meeting its own climate ambitions.

2. Baseline Emissions Footprint

Baseline emissions represent the greenhouse gases generated prior to implementing our carbon reduction strategies.

Baseline Year: 2021

Emissions	Total (tCO ₂ e)
Scope 1	960.45
Scope 2 (Market-based)	373.15
Scope 3 (Included Sources)	Not reported
Total Baseline Emissions	1,333.60

Note: Scope 3 emissions were not quantified at this stage; this gap has since been addressed with the completion of a full Scope 3 inventory in 2025.

3. Current Emissions Reporting (2025)

Sharpak Healthcare reports Scope 1, Scope 2 (both market-based and location-based), and Scope 3 emissions in accordance with the Greenhouse Gas Protocol and NHS Evergreen reporting requirements.

Emissions Summary (2025)

Source	Emissions (tCO ₂ e)
Scope 1	31.12
Scope 2 (Market-based)	0.00
Scope 2 (Location-based)	259.94
Scope 3 (Included Sources)	1,569

In 2025, Sharpak Healthcare achieved zero market-based Scope 2 emissions for the fourth consecutive year through continued use of certified renewable electricity. Location-based emissions remain measurable due to the carbon intensity of the UK grid.

3A. Scope 3 Emissions Reporting (2025)

Sharpak Healthcare completed its first full Scope 3 greenhouse gas inventory in 2025, covering all relevant value-chain categories in accordance with the GHG Protocol. This assessment is based on ISO 14067-verified primary LCA data for the Sharpak product portfolio, providing a robust and auditable baseline for future reduction planning.

Scope 3 Emissions Breakdown (2025)

Category Grouping	Emissions (tCO ₂ e)	% of Total Scope 3	Description
Product Value Chain	1,528	97.37%	Raw materials, manufacturing, distribution, product use & clinical waste incineration
Operational & Energy Impacts	25	1.58%	Fuel- and energy-related activities not included in Scope 1 & 2
Business Travel & Commuting	16.5	1.05%	Staff travel, commuting, grey-fleet mobility emissions
Total Scope 3 Emissions (2025)	1,569	100%	—

The 2025 Scope 3 assessment confirms that product-related emissions dominate the value chain, accounting for over 97% of total Scope 3 emissions. Clinical waste incineration at end-of-life represents the single largest contributor, followed by upstream material production and product distribution.

Operational impacts and staff mobility represent a combined 2.6% of the Scope 3 footprint.

This dataset now forms Sharpak Healthcare’s official Scope 3 baseline and will be used to:

- track annual progress against reduction targets,
- support NHS Evergreen compliance,
- identify decarbonisation hotspots,
- inform product design improvements and material selection, and
- guide customer transition to multi-use systems such as the Sharpak Zero range.

4. Emission Reduction Targets

Scope 1 & 2 Targets

- Scope 1: Sustain the 96% reduction achieved since 2021 by removing carbon-intensive fuels.
- Energy Intensity: Continue improving operational efficiency through investments in modern, energy-efficient equipment.
- NHS Alignment: Maintain full compliance with PPN 06/21 and NHS Evergreen reporting for future contract bids.

Scope 3 Reduction Targets

The 2025 Scope 3 footprint totals 1,569 tCO₂e, with 97.37% linked to product-related emissions—particularly clinical waste incineration at end-of-life.

Sharpak Healthcare commits to:

- 20% reduction in Scope 3 emissions intensity per unit by 2030, driven by product redesign, higher recycled content, and growth of the Sharpak Zero multi-use range.
- Supporting NHS partners in transitioning from single-use to multi-use systems.
- Annual Scope 3 reassessments to track progress, validate reductions, and identify emerging hotspots.

5. Carbon Reduction Projects

Completed Projects (2021–2025)

- Fuel Switching: Full elimination of heavy oil by 2022 and significant reductions in natural gas consumption.
- Renewable Electricity: 100% renewable electricity (REGO-backed) since 2022, achieving four consecutive years of zero market-based Scope 2 emissions.
- Operational Efficiency: Upgraded to energy-efficient equipment and improved insulation across manufacturing sites.
- Waste Management: Achieved and maintained zero waste to landfill.

Future Initiatives (2026 and Beyond)

- Energy-Efficient Machinery: Ongoing capital investment in next-generation injection moulding equipment to reduce grid electricity consumption (Scope 2, location-based).
- Sharpak Zero Scaling: Continuing to expand the multi-use product range to support NHS decarbonisation.

- Supply Chain Engagement: Enhanced supplier assessments to improve Scope 3 reporting and collaboration on emissions reduction.
- Scope 3 Reduction Projects (2026 and Beyond)
 - Product Value Chain (97% of Scope 3):
Expansion of the Sharpak Zero multi-use range to progressively replace single-use products.
 - Operational Value Chain (1.6%):
Investigation of onsite solar PV to reduce well-to-tank electricity emissions.
 - Travel & Commuting (1%):
Further development of EV charging infrastructure at Sharpak sites.

6. Declaration and Sign-off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance.

Signed on behalf of Sharpak Healthcare Ltd: _____



Kieron King, Standards & Sustainability Manager

Date: 24th March 2026